3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Unknown
1
Sponsor Class
OTHER
5
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Breast Neoplasms
31
Advanced Solid Tumors
25
Advanced Solid Tumor
24
Carcinoma, Non-Small-Cell Lung
20
Neoplasms
15
Solid Tumor
12
Prostatic Neoplasms
12
Multiple Myeloma
12
Neoplasm Metastasis
11
Recurrence
10
Pancreatic Neoplasms
10
Small Cell Lung Carcinoma
9
Ovarian Neoplasms
9
Lung Neoplasms
9
Stomach Neoplasms
8
Melanoma
8
Lymphoma, Large B-Cell, Diffuse
8
Leukemia, Myeloid, Acute
8
Carcinoma, Hepatocellular
8
Triple Negative Breast Neoplasms
7
Sarcoma
7
Colorectal Neoplasms
7
Uterine Cervical Neoplasms
6
Solid Tumors
6
Carcinoma, Transitional Cell
5
Advanced Solid Tumour
5
Squamous Cell Carcinoma of Head and Neck
4
Nasopharyngeal Carcinoma
4
Myelodysplastic Syndromes
4
Lymphoma
4
Interventions
Cyclophosphamide
17
blinatumomab
16
fludarabine
13
Vincristine
11
Cytarabine
10
tisagenlecleucel
8
pegaspargase
8
nilotinib
8
Methotrexate
8
Inotuzumab Ozogamicin
8
Clofarabine
8
venetoclax
7
Dexamethasone
7
asparaginase erwinia chrysanthemi recombinant
6
Dasatinib
6
Azacitidine
5
AP 1903 reagent
5
aflibercept
4
Mercaptopurine
4
Imatinib Mesylate
4
Filgrastim
4
Etoposide
4
Drug Therapy
4
Daunorubicin
4
ponatinib
3
Sensitivity and Specificity
3
Mitoxantrone
3
Immunotherapy, Adoptive
3
Granulocyte Colony-Stimulating Factor
3
CPX-351
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Precursor Cell Lymphoblastic Leukemia-Lymphoma
×
Injections
×
Clear all
NCT03709914
2023-09-15
Pediatric_PK
Nabriva Therapeutics AG
Phase 1
Unknown
21 enrolled